Q4 2022
Released Mar 9, 2023, before the open
10-K filed Mar 9, 2023, 68 days after period end · 0001628280-23-007266
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$39.28M-$39.28M derivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$38,686,000—
Operating Cash Flowderived-$30,713,000N/M
Free Cash Flowderived-$35,527,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|
| Net Income | -$39.28M | -$62.91M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR